Patients with rheumatoid arthritis with anemia taking NSAIDs
Conditions
Interventions
Treatment with mesalazine
Sponsors
Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)Rheumatoid arthritis patients aged older than 20y and younger than 70 y who were taking NSAIDs for more than 3 mo and will take NSAIDs for the additional 8 w. 2)The patients with anemia (Hg levels lower than 13.8 g/dl (men) 12.0 g/dl(women) and without abnormalities in the liver and renal function tests.
Exclusion criteria
Exclusion criteria: Patients treated with mesalazine or salicylic acid 2 weeks proior to the entry of this study. Patients with escalating the dose of anti-rheumatoid arthritis drugs such as aspirins or proton pump inhitors. Patients took gastroprotective agents such as rebamipide, ecabet sodium, misoprostol. Patients being treated with high-dose corticosteroids (more than 15 mg/day of prednisolone. Patients treated with biologics 90 days prior to the entry of this study. Patients who were allergic to or suffered from side effects by mesalazine of salicylic acids. Patients incapable of swallowing capsule endoscopy. Patients suspicious of intestinal strictures. Patients with malignancies. Pregnancy or possible pregnancy. Patients with side effects by other previous clinical studies. Patients who were considered unsuitable for this study by doctors.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Endoscopic findings by capsule endoscopy. Side effects due to the mesalazine treatment. | — |
Secondary
| Measure | Time frame |
|---|---|
| Patients' joint and abdominal symptoms. Serum cytokines. Fecal calprotectin | — |
Countries
Japan
Outcome results
None listed